ECU-MG-302, A Phase III, Open-label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)

Trial Profile

ECU-MG-302, A Phase III, Open-label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 13 Sep 2017 Results presented in Alexion Pharmaceuticals media release
    • 13 Sep 2017 According to an Alexion Pharmaceuticals media release, James F. Howard, MD, Department of Neurology at the University of North Carolina is a lead investigator of the study.
    • 13 Sep 2017 Interim results (n =105) are presented at the annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) in Phoenix, Arizona.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top